Showing 1641-1650 of 2526 results for "".
- Allergan Plans Sales of Women’s Health, Infectious Disease Unitshttps://modernod.com/news/allergan-plans-sales-of-womens-health-infectious-disease-units/2480131/Allergan plans to sell off its women’s health and infectious disease businesses as Chief Executive Brent Saunders works to end the steep slide in its share price over the last year, according to a
- California Optometrists Caution Patients About Unapproved, Online Vision Tests After FDA Warninghttps://modernod.com/news/california-optometrists-caution-patients-about-unapproved-online-vision-tests-after-fda-warning/2480161/The California Optometric Association cautioned California consumers that self-administered “vision tests” conducted online come with significant safety concerns and appear to violate federal law, according to a news release. In a letter to the California Attorney General, the organization
- Prevent Blindness Launches Online Patient Resource on Insurance Benefits for Eye Carehttps://modernod.com/news/prevent-blindness-launches-online-patient-resource-on-insurance-benefits-for-eye-care/2484307/With open enrollment in Medicare and the Affordable Care Act Marketplace underway, Prevent Blindness has launched a new online educational resource to help individuals and families better understand their vision and eye care benefits. According to Prevent Blindness, the new guide, “Understa
- Exploring a Connection Between GLP-1 Drugs and Vision Losshttps://modernod.com/news/exploring-a-connection-between-glp-1-drugs-and-vision-loss/2484306/Two studies presented at the 2025 AAO Annual Meeting explored a possible connection between GLP-1 drugs and vision loss. Using data from the World Health Organization’s global database of drug safety reports, researchers at the University of Ottawa Eye Institute, University of Tor
- Avisi Technologies Announces Positive 12-Month Clinical Data on VisiPlate Aqueous Shunthttps://modernod.com/news/avisi-technologies-announces-positive-12-month-clinical-data-on-visiplate-aqueous-shunt/2484305/Avisi Technologies announced positive 12-month clinical data on its VisiPlate Aqueous Shunt from the VITA trial during the 2025 AAO Annual Meeting. The study was presented by Jonathan Myers, MD, chief of the glaucoma service at Wills Eye Hospital, Thomas Jefferson University, in Philadelphia.
- Duke Eye Center Implants Cell-Based Therapy for MacTelhttps://modernod.com/news/duke-eye-center-implants-cell-based-therapy-for-mactel/2484304/Duke Eye Center announced that its team is the first at a US academic medical center to implant a new commercially available cell-based gene therapy for macular telangiectasia type 2 (MacTel). No treatment was available to slow the progression of MacTel until the FDA approved revakinagene taroret
- Celularity Enters Strategic Partnership with DefEYE to Advance Regenerative Therapies in Eye Carehttps://modernod.com/news/celularity-enters-strategic-partnership-with-defeye-to-advance-regenerative-therapies-in-eye-care/2484300/Celularity announced a strategic partnership with DefEYE, a newly established ophthalmic product and technology company. Under the terms of the agreement, Celularity has executed an exclusive license and pricing arrangement with DefEYE, following Celularity&rs
- Eyederm Cosmetics Launches Three New Beauty Products for the Eyehttps://modernod.com/news/eyederm-cosmetics-launches-three-new-beauty-products-for-the-eye/2484296/Eyederm Cosmetics announced the launch of three new products: Under Eye Patches, Microneedle Eye Patches, and Microneedle Forehead Patches. Created by board-certified eye care professionals, Eyederm said its new collec
- Regeneron Delays Regulatory Submission for Eylea HD Pre-Filled Syringe After CRLhttps://modernod.com/news/regeneron-delays-regulatory-submission-for-eylea-hd-pre-filled-syringe-after-crl/2484294/In its third quarters earnings filing, Regeneron said it received another complete response letter (CRL) from the FDA for its pre-filled syringe supplemental BLA (sBLA) for Eylea HD (aflibercept injection 8 mg). The sole approvability issue cited in the CRL relates to unresolved inspection findin
- VEO Ophthalmics Partners with PeriVision to Bring VisionOne VR Visual Field Platform to UShttps://modernod.com/news/veo-ophthalmics-announces-us-launch-of-visionone-vr-visual-field-platform/2484203/VEO Ophthalmics announced the availability of the VisionOne VR Visual Field platform in the United States through a strategic partnership with PeriVision. This collaboration brings Switzerland-based PeriVision’s patented AI visual field-testing algorithm (SORS) to